SSC
ANTX icon

Spruce Street Capital’s AN2 Therapeutics ANTX Stock Holding History

Spruce Street Capital’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.04M Hold
1,661,073
– – 1.58% 19
2026
Q1 		$5.58M Buy
+1,661,073
New +$3.43M 1.34% 23

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.89B AUM 55.94% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Spruce Street Capital's ANTX Position: Q2 2026 in Review

Spruce Street Capital held its AN2 Therapeutics (ANTX) position steady in Q2 2026 at 1,661,073 shares worth $8.04M. The position accounts for 1.58% of the portfolio, ranked #19.

Spruce Street Capital first reported a position in ANTX in Q1 2026 and has held it in 2 quarters since. 59 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Spruce Street Capital held 1,661,073 shares of AN2 Therapeutics worth $8.04M as of Q2 2026.
  • Spruce Street Capital left its AN2 Therapeutics share count unchanged in Q2 2026.
  • AN2 Therapeutics made up 1.58% of Spruce Street Capital's portfolio in Q2 2026, its #19 holding.
  • Spruce Street Capital first reported a position in AN2 Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 59 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Spruce Street Capital's 13F filing for Q2 2026, filed 13 Aug 2026.